GREGORY A LIZEE to CD8-Positive T-Lymphocytes
This is a "connection" page, showing publications GREGORY A LIZEE has written about CD8-Positive T-Lymphocytes.
Connection Strength
1.785
-
Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. Cells. 2021 09 10; 10(9).
Score: 0.446
-
Detection and characterization of a novel subset of CD8?CD57? T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res. 2012 May 01; 18(9):2465-77.
Score: 0.229
-
Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One. 2011; 6(8):e22939.
Score: 0.221
-
Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
Score: 0.216
-
TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy. J Immunother. 2010 May; 33(4):371-81.
Score: 0.203
-
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods. 2008 Feb 29; 331(1-2):13-26.
Score: 0.170
-
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res. 2006 Oct 01; 12(19):5801-8.
Score: 0.158
-
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86.
Score: 0.062
-
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K? Inhibition in PTEN Loss Melanoma. Clin Cancer Res. 2019 11 01; 25(21):6406-6416.
Score: 0.024
-
RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun. 2018 09 25; 9(1):3919.
Score: 0.023
-
NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016 May 24; 113(21):5999-6004.
Score: 0.019
-
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012 Apr 15; 18(8):2326-35.
Score: 0.014